SOURCE: Eisai Inc.

June 01, 2005 08:00 ET

Eisai Inc. Announces Appointment of Vice President of Quality

TEANECK, NJ -- (MARKET WIRE) -- June 1, 2005 -- Eisai Inc. today announces the immediate appointment of Lyn D. Olson, Ph.D., as Vice President of Quality at the company's pharmaceutical production and formulation research and development facility in Research Triangle Park, North Carolina. In her role, Dr. Olson will oversee all aspects of quality control and quality assurance.

Dr. Olson joined Eisai from Protein Design Laboratories, Inc. where she served as vice president of quality and regulatory compliance. Her responsibilities included preclinical/clinical quality assurance, manufacturing quality assurance, quality control and validation.

Dr. Olson began her career at the US Food and Drug Administration as a senior regulatory review officer and research scientist. She subsequently held prominent quality related positions at Boehringer Mannheim Corporation and Centocor, Inc.

"Dedication to ongoing quality and compliance remains a top priority at Eisai," said Lonnel Coats, President & COO. "We are confident Dr. Olson will continue to ensure that our products contribute to Eisai's mission of delivering value to patients and their families."

About Eisai Inc.

Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products in more than 30 countries. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2 billion in fiscal year 2004 (year ended March 31, 2005).

Eisai Inc. employs approximately 1,200 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. Between 1998 and 2004, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to No. 19.

Contact Information

  • Contacts:

    Cathy Pollini
    Eisai Inc.
    201/287-2052

    Anna Blank
    Hill & Knowlton
    212/885-0522